{"id":648088,"date":"2023-04-19T18:56:02","date_gmt":"2023-04-19T18:56:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=648088"},"modified":"2023-04-19T18:56:02","modified_gmt":"2023-04-19T18:56:02","slug":"acute-myeloid-leukemia-market-to-exhibit-moderate-growth-rate-during-the-forecast-period-20222032-investigates-delveinsight-key-companies-otsuka-pharma-genentech-inc-sanofi-abbvie","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-myeloid-leukemia-market-to-exhibit-moderate-growth-rate-during-the-forecast-period-20222032-investigates-delveinsight-key-companies-otsuka-pharma-genentech-inc-sanofi-abbvie_648088.html","title":{"rendered":"Acute Myeloid Leukemia Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies &#8211; Otsuka Pharma, Genentech, Inc., Sanofi, AbbVie"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1681913821.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Acute Myeloid Leukemia Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - Otsuka Pharma, Genentech, Inc., Sanofi, AbbVie\" src=\"https:\/\/www.abnewswire.com\/uploads\/1681913821.jpeg\" alt=\"Acute Myeloid Leukemia Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - Otsuka Pharma, Genentech, Inc., Sanofi, AbbVie\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cAcute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Acute Myeloid Leukemia.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Acute Myeloid Leukemia, historical and forecasted epidemiology as well as the Acute Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Acute Myeloid Leukemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acute-myeloid-leukemia-aml-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acute Myeloid Leukemia Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Acute Myeloid Leukemia Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Acute Myeloid Leukemia market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period <strong>(2019-2032)<\/strong><\/li>\n<li>According to the Surveillance, Epidemiology, and End Results <strong>(SEER)<\/strong> study program, the rate of new cases of acute myeloid leukemia was <strong>4.3 per 100,000 men<\/strong> and women per year in the United States<\/li>\n<li>According to the Cancer Research UK, Acute Myeloid Leukemia incidence is strongly related to age, with the highest incidence rates being in older people. In the UK in 2016-2018, on average each year more than <strong>4 in 10 new cases<\/strong> (42%) were in people aged 75 and over<\/li>\n<li><strong>Key Acute Myeloid Leukemia Companies:<\/strong> Otsuka Pharmaceutical Co., Ltd., Genentech, Inc., Sanofi, AbbVie, Clavis Pharma, AstraZeneca, Astex Pharmaceuticals, Inc., BioSight Ltd., Novartis, Gilead Sciences, Takeda Oncology, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Orca Bio, Gilead Sciences, GlycoMimetics Incorporated, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research &amp; Development, LLC, Immune-Onc Therapeutics, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, and others<\/li>\n<li><strong>Key Acute Myeloid Leukemia Therapies:<\/strong> ASTX727, Chimerix, IO-202, OCV-501, Azacitidine, clofarabine, Venetoclax, Elacytarabine, AZD1152, guadecitabine, BST-236, Uproleselan, Midostaurin, Magrolimab, TCB008, Dociparastat, ADI-PEG, Cytarabine, and others<\/li>\n<li>The Acute Myeloid Leukemia epidemiology based on gender analyzed that acute myeloid leukemia (AML) is more prominent in males in comparison to females<\/li>\n<li>The Acute Myeloid Leukemia market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Myeloid Leukemia pipeline products will significantly revolutionize the Acute Myeloid Leukemia market dynamics.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Myeloid Leukemia Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Acute myeloid leukemia (AML) (also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukaemia) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and\/or other tissues. AML can involve tissues outside the bone marrow and blood, including lymph nodes, the brain, skin, and other parts of the body.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Acute Myeloid Leukemia Market Report&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-myeloid-leukemia-aml-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/acute-myeloid-leukemia-aml-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Acute Myeloid Leukemia Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Myeloid Leukemia Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Acute Myeloid Leukemia market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Acute Myeloid Leukemia<\/li>\n<li>Prevalent Cases of Acute Myeloid Leukemia by severity<\/li>\n<li>Gender-specific Prevalence of Acute Myeloid Leukemia<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Acute Myeloid Leukemia<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Acute Myeloid Leukemia epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-myeloid-leukemia-aml-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acute Myeloid Leukemia Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Myeloid Leukemia Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Myeloid Leukemia market or expected to get launched during the study period. The analysis covers Acute Myeloid Leukemia market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Acute Myeloid Leukemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Myeloid Leukemia Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ASTX727:<\/strong> Astex Pharmaceuticals<\/li>\n<li><strong>Chimerix:<\/strong> Dociparstat Sodium<\/li>\n<li><strong>IO-202:<\/strong> Immune Onc<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Acute Myeloid Leukemia market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-myeloid-leukemia-aml-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acute Myeloid Leukemia Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Acute Myeloid Leukemia Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Acute Myeloid Leukemia Companies:<\/strong> Otsuka Pharmaceutical Co., Ltd., Genentech, Inc., Sanofi, AbbVie, Clavis Pharma, AstraZeneca, Astex Pharmaceuticals, Inc., BioSight Ltd., Novartis, Gilead Sciences, Takeda Oncology, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Orca Bio, Gilead Sciences, GlycoMimetics Incorporated, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research &amp; Development, LLC, Immune-Onc Therapeutics, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, and others<\/li>\n<li><strong>Key Acute Myeloid Leukemia Therapies:<\/strong> ASTX727, Chimerix, IO-202, OCV-501, Azacitidine, clofarabine, Venetoclax, Elacytarabine, AZD1152, guadecitabine, BST-236, Uproleselan, Midostaurin, Magrolimab, TCB008, Dociparastat, ADI-PEG, Cytarabine, and others<\/li>\n<li><strong>Acute Myeloid Leukemia Therapeutic Assessment:<\/strong> Acute Myeloid Leukemia current marketed and Acute Myeloid Leukemia emerging therapies<\/li>\n<li><strong>Acute Myeloid Leukemia Market Dynamics:<\/strong> Acute Myeloid Leukemia market drivers and Acute Myeloid Leukemia market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Acute Myeloid Leukemia Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Acute Myeloid Leukemia Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Acute Myeloid Leukemia companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-myeloid-leukemia-aml-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acute Myeloid Leukemia Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Acute Myeloid Leukemia Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Acute Myeloid Leukemia<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Acute Myeloid Leukemia<\/p>\n<p style=\"text-align: justify;\">4. Acute Myeloid Leukemia Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Acute Myeloid Leukemia Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Acute Myeloid Leukemia Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Acute Myeloid Leukemia Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Acute Myeloid Leukemia&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Acute Myeloid Leukemia Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Acute Myeloid Leukemia Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Acute Myeloid Leukemia Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Acute Myeloid Leukemia Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Acute Myeloid Leukemia Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Acute Myeloid Leukemia Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Acute Myeloid Leukemia Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Acute Myeloid Leukemia Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Acute Myeloid Leukemia Appendix<\/p>\n<p style=\"text-align: justify;\">18. Acute Myeloid Leukemia Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75613.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=acute-myeloid-leukemia-market-to-exhibit-moderate-growth-rate-during-the-forecast-period-20222032-investigates-delveinsight-key-companies-otsuka-pharma-genentech-inc-sanofi-abbvie\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 8774225362<br \/><strong>Address:<\/strong>27 Drydock Ave  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Boston<br \/><strong>State:<\/strong> MA<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=acute-myeloid-leukemia-market-to-exhibit-moderate-growth-rate-during-the-forecast-period-20222032-investigates-delveinsight-key-companies-otsuka-pharma-genentech-inc-sanofi-abbvie\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s \u201cAcute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Acute Myeloid Leukemia. DelveInsight&rsquo;s &ldquo;Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032&Prime; report offers an in-depth understanding of the Acute Myeloid Leukemia, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/acute-myeloid-leukemia-market-to-exhibit-moderate-growth-rate-during-the-forecast-period-20222032-investigates-delveinsight-key-companies-otsuka-pharma-genentech-inc-sanofi-abbvie_648088.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-648088","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/648088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=648088"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/648088\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=648088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=648088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=648088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}